Clinuvel Pharmaceuticals Limited ( (AU:CUV) ) has shared an update.
JPMorgan Chase & Co. and its affiliates have reduced their voting power in Clinuvel Pharmaceuticals Ltd, a company in the biotechnology sector, from 6.26% to 5.26%. This change reflects a decrease in the number of ordinary shares held by JPMorgan, which may impact their influence in company decisions.
More about Clinuvel Pharmaceuticals Limited
YTD Price Performance: -6.58%
Average Trading Volume: 459
Technical Sentiment Signal: Buy
Current Market Cap: $365M
For an in-depth examination of CUV stock, go to TipRanks’ Stock Analysis page.